News

Kura Oncology Set to Announce Q3 Financial Performance Soon

Kura Oncology Set to Announce Q3 Financial Performance Soon

Kura Oncology Set to Announce Q3 Financial Performance

Kura Oncology, Inc. (Nasdaq: KURA), a visionary biopharmaceutical company, is on the brink of announcing its financial results for the third quarter of 2024. The anticipation builds as the company is scheduled to release these earnings following the close of U.S. financial markets. This event is set for November 7, 2024, at 4:30 p.m. ET, showcasing the company’s commitment to transparency and communication with its investors.

Accessing the Live Conference Call

Investors and interested parties can participate in a live conference call by dialling (800) 225-9448 for domestic callers or (203) 518-9708 for those calling from outside the United States. Attendees will need to provide the conference ID: KURAQ3 to gain access to what promises to be an informative discussion regarding the company’s financial standing and strategic updates.

About Kura Oncology

Kura Oncology is dedicated to developing precision medicines that target cancerous cells. It is at the forefront of creating innovative treatments that are specifically designed to address the complexities of various cancer types. Kura’s drug portfolio features small molecule candidates aimed at inhibiting critical cancer signaling pathways, with a focus on delivering effective solutions to patients in need.

Pioneering Cancer Therapies

A standout candidate in Kura's pipeline is Ziftomenib, an oral medication that targets the menin-KMT2A protein-protein interaction. It has received Breakthrough Therapy Designation due to its potential in treating relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). This significant progress reflects Kura's commitment to advancing treatment methodologies in oncology.

Ongoing Clinical Trials

Kura Oncology is currently advancing several clinical trials aimed at exploring the efficacy of Ziftomenib in combination therapies for newly diagnosed and relapsed/refractory cases of AML. This includes the KOMET-001 trial, which has completed patient enrollment, highlighting Kura’s proactive approach in the clinical space.

Exploring Innovative Inhibitors

In addition to Ziftomenib, Kura is evaluating KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation study. The aim is to assess its safety and efficacy both as a standalone treatment and in conjunction with existing therapies. This innovative approach offers hope for improved patient outcomes.

Combination Therapy Research

Among the promising candidates, Tipifarnib stands out as a potent farnesyl transferase inhibitor currently undergoing investigation in a Phase 1/2 trial. It is being tested in combination with alpelisib for patients suffering from PIK3CA-dependent head and neck squamous cell carcinoma. Kura's commitment to exploring combination therapies underscores its strategy to enhance treatment effectiveness.

Staying Informed on Developments

As a trailblazer in biopharmaceutical innovations, Kura Oncology encourages stakeholders to stay informed about its developments. The company's website serves as a valuable resource for the latest information regarding its therapeutic advancements and operational updates.

Company Contact Information

Kura Oncology prioritizes communication with both investors and the media. For inquiries, please contact:

Investors:
Pete De Spain
Executive Vice President, Investor Relations & Corporate Communications
(858) 500-8833
pete@kuraoncology.com

Media:
Cassidy McClain
Vice President
Inizio Evoke Comms
(619) 849-6009
cassidy.mcclain@inizioevoke.com

Frequently Asked Questions

When will Kura Oncology announce its Q3 financial results?

Kura Oncology will announce its third quarter financial results on November 7, 2024, after the close of U.S. markets.

How can I participate in the Kura Oncology conference call?

To join the live conference call, dial (800) 225-9448 for domestic calls or (203) 518-9708 for international calls and enter the conference ID: KURAQ3.

What is Ziftomenib used for?

Ziftomenib is an oral medication aimed at treating relapsed/refractory NPM1-mutant AML and has received Breakthrough Therapy Designation.

What ongoing trials is Kura Oncology conducting?

Kura is currently conducting clinical trials for Ziftomenib, KO-2806, and Tipifarnib to evaluate their effectiveness in various types of cancer.

How can I stay updated on Kura Oncology's developments?

You can visit Kura’s official website to keep up with the latest updates and information on their ongoing research and treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

QORAI CORP's Q4 Nexus: A New AI Frontier

Updated Category News Views 51

Breakthrough in AI: Enter Q4 Nexus It's not every day you see a tech player emerge with something genuinely fresh—QORAI CORP is shaking up the scene with its Q4 Nexus platform. This isn't just another AI model upgrade. We're talking about a rethink of the very architecture we rely on to power these systems. Founder Robby Joshi's brainchild, Q4 Nexus, jazzes up the AI...

Continue Reading
EPG's New Malaysian Factory: A US$120M Commitment

Updated Category News Views 129

In the hustle and bustle of manufacturing, EPG Modular Data Center has hit a landmark moment. They're not just slapping up another building—they're carving out a piece of future tech infrastructure with their fresh Malaysia FIZ Factory. Investing in Regional Strength When you pump US$120 million into a project, you're doing more than sinking cash into concrete—you're...

Continue Reading
Teneo Expands Financial Advisory in Canada, Eyes Talent

Updated Category News Views 90

Turning the Maple Leaf Over: Teneo's Move Alright, here's the scoop: Teneo is muscling its way north, into Canada, to flex its Financial Advisory chops. With a lineup of 60 professionals already setting the pace across Toronto, Montreal, and Calgary, this move isn’t just smoke—it’s a full-fledged expansion. They're under the hood, tinkering away to beef up...

Continue Reading
Equinix Launches SG6: A Boost for Singapore’s AI Economy

Updated Category News Views 163

Singapore's Strategic Role in Digital Evolution How do you blend cutting-edge tech with sustainability? Equinix has a recipe, and it’s dishing it out now in Singapore with the launch of SG6, their sixth International Business Exchange™ data center. We’re talking a near $290 million tab here—serious money for serious infrastructure, all right smack dab in one of...

Continue Reading
CoffeeBarista.com Launches Amid High U.S. Coffee Craze

Updated Category News Views 54

Fresh Grounds: CoffeeBarista.com Enters the Brewing Scene Alright, folks, let's cut to the chase. Digital Information Resources, the tech whiz that's been accumulating niche online properties like they're baseball cards, decided it's time to dive headfirst into the caffeinated waters with CoffeeBarista.com. Fancy name for a platform dedicated to everything bean juice,...

Continue Reading
Kestrel Group Faces Financial Hit Despite Revenue Growth

Updated Category News Views 97

Kestrel's Financial Rollercoaster Continues Here's the deal with Kestrel Group, folks. They just dropped their Q3 2026 financials, and it's a mixed bag. The top line's looking solid with total revenues hitting $4.8 million, riding high on a 203% jump in Program Services fee income. But dig a little deeper, and there's a $16.4 million net loss staring us in the face....

Continue Reading
Luxury Dog Resort Opens in Dallas on November 14th

Updated Category News Views 93

Dallas Pooches Get Star Treatment It's about time our furry pals in Dallas got a piece of high society. This ain't your run-of-the-mill doggie daycare opening a new outlet. The Wags Club, with its roots deep in Los Angeles luxury, is setting up shop near Love Field, giving Texan pups a taste of the good life. Visitors on November 14 better dress their best, and that's not...

Continue Reading
Pen Needles Market to Hit $3.37B by 2031: Growth Ahead

Updated Category News Views 110

Big Numbers in the Needle Game When you're staring down the numbers popping out of this pen needles market projection, it's hard to ignore—shooting from a respectable $2.16 billion in 2026 to a hefty $3.37 billion by 2031. We're talking a 9.3% CAGR that'll have investors pulling out their calculators or maybe rubbing their hands in downright glee, depending on their...

Continue Reading
Investor Bidding on Off-Market Homes Surges 35% Higher

Updated Category News Views 109

Investor Frenzy in Off-Market Real Estate Looking at the real estate puzzle today, one might spot an unexpected surge in enthusiasm for off-market residential properties. We've got iFinder Offers, a real estate platform that's made it its business to connect the dots between homeowners and a gaggle of over 325 hungry investors. And according to their magic spreadsheets,...

Continue Reading
Maritime Injury Law: Neidzwski Talks Sea Changes

Updated Category News Views 54

Legal waters are as choppy as the seas themselves, especially in the maritime injury law arena. Nicholas J. Neidzwski, a maritime injury attorney and partner at BoatLaw, LLP, recently waded into these turbulent waters at the 2026 Pacific Admiralty Seminar. This isn’t just any gathering; it’s the West Coast’s legal beacon on all things maritime, drawing in industry...

Continue Reading

Top 5 Most Recently Viewed Articles

Regency Affiliates Enhances Shareholder Value with Buyback

Updated Category News Views 44

Regency Affiliates' Strategic Share Repurchase Announcement Regency Affiliates, Inc. (OTC Pink: RAFI) has officially revealed that it has successfully acquired 331,500 shares of its outstanding common stock in a recent transaction. This move is aimed at enhancing shareholder value and demonstrates the company's commitment to its investors. The acquisition was made through...

Continue Reading
Five Below's Stock Insights: Mizuho's Neutral Stance Explained

Updated Category News Views 63

Mizuho's Neutral Rating on Five Below: What It Means Recently, Mizuho maintained its Neutral rating for Five Below (NASDAQ: FIVE) while keeping the price target steady at $85.00. This decision stems from observed changes in the retailer's operational strategies. Notably, Five Below is bringing back self-checkout systems in certain locations, moving away from...

Continue Reading
Analyzing Conagra Brands’ Upcoming Earnings Release Expectations

Updated Category News Views 74

Introduction to Conagra Brands' Earnings Announcement Conagra Brands (NYSE: CAG) is preparing to unveil its quarterly earnings soon, making it a crucial time for investors to pay attention. With significant market expectations riding on this announcement, it is essential to understand various elements that contribute to the company's financial landscape and its upcoming...

Continue Reading
Otto Aerospace's Groundbreaking Aircraft Order with Flexjet

Updated Category News Views 437

Otto Aerospace Partners with Flexjet for Aircraft Order Otto Aerospace is making waves in the aviation industry with a groundbreaking announcement about its first fleet customer. The company has named Flexjet as the launch customer for the new, next-generation Phantom 3500 business jet. This innovative aircraft is designed to be ultra-efficient and incorporates advanced...

Continue Reading
Wondershare Filmora Unveils Exciting AI Music Challenge

Updated Category News Views 679

Wondershare Filmora Launches AI-Powered Music Challenge Wondershare Filmora, a leader in video creativity software, has made waves with its latest initiative—the "Can You Feel the Beat?" music challenge. This exciting feature is now prominently displayed on the homepage of Google Play, making it easier than ever for users to engage with their creativity through music....

Continue Reading